SwingTrade Member Forum

[RIGATONI]

~MLHP News...

Millenia Hope Appoints Dr. Wilfred Sylvain Nambei as a Member of Its Scientific Committee
Clinical Tests Performed With MMH MALAREX(TM) and Its New BEBE MMH MALAREX(TM) for Young Children are Very Positive
MONTREAL, Jun 1, 2004 /PRNewswire-FirstCall via COMTEX/ --
Millenia Hope Inc. a Biotech Corporation (OTC Bulletin Board: MLHP) (BERLIN: MLF) is pleased to announce that Dr. Wilfred Sylvain Nambei has joined its Scientific Committee after a highly successful trial of Millenia Hope's anti-malarial agent for young children, BEBE MMH MALAREX(TM). The official results of this study will be released in the near future, as soon as they become available. A previously run trial of MMH MALAREX(TM), by Dr, Nambei in Bangui, the Central African Republic, also yielded excellent clinical results.

Dr. Nambei received his Pharmacology degree in 1996, at the Medical and Pharmacology Faculty of the University Cheikh Anta Diop de Dakar, Senegal, and his PhD in Pharmacology, with great Honors, at the same University in 1997. Dr. Nambei received his degree in General Immunology and Immunophysics in infectious diseases from the Institut Pasteur, Paris, France, in 1999, the year in which he also completed a D.E.A. in Chemistry and Biochemistry, in natural products, at the faculty of Natural Sciences and Technology at the UCAD, Senegal.

Dr. Nambei has been the Chief of Pharmacology and Medicine at l'Hopital Communautaire de Bangui, Central African Republic, since 2002 and the chief of Parasitology and Microbiology at Cerphameta, University of Bangui since 2000. From 1995 onward, he has worked at a variety of posts, at The Institut Pasteur of Dakar, and at other recognized medical institutions. Dr. Nambei has published many scholarly works regarding his much recognized research on Plasmodium Falciparum (malaria) parasites and their effects on blood cells.

"We are pleased to have such a renowned scientist join our Scientific Committee," said Leonard Stella, CEO of Millenia Hope. "This again shows that our anti-malarial product, MMH MALAREX(TM), is being well received in countries in which malaria is endemic."

About Millenia Hope:

Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.

Safe Harbour Statement:

Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements". Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.

This release was issued through Major Newswire ( http://www.majornewswire.com ).

SOURCE Millenia Hope Inc.

Raymond L. Roy, Executive Vice President of Millenia Hope Inc.,
[phone], [e-mail]
http://www.milleniahope.com

--------------------------------------------------------------------------------

Copyright (C) 2004 PR Newswire. All rights reserved.

News provided by